title: Quantitative assessment of protection in experimental syphilis.
abstract: Protection in experimental rabbit syphilis has been previously assessed by lesion development following intradermal challenge with Treponema pallidum. We have recently reported that passive immunization using monoclonal antibody M131 conveys partial protection as evidenced by significant lesion delays following intradermal challenge. To determine whether such delays in time to lesion appearance corresponded to decreases in the numbers of spirochetes, we used real-time PCR to quantitate T. pallidum genomic DNA copy numbers in lesion biopsies taken throughout the course of lesion development. Three groups of animals were given one prechallenge passive immunization with immune rabbit serum (IRS), M131, or control monoclonal antibody (CMAb) and then challenged with treponemal admixtures of IRS or monoclonal antibody in normal rabbit serum (NRS). As compared to the CMAb NRS controls, delays in the mean time to lesion appearance of 5.8 days for IRS and 8.8 days for M131 were observed. At the earliest time point (10 days postchallenge), real-time PCR showed a mean T. pallidum DNA copy number per mug of rabbit DNA in the CMAb NRS group of 7.65 x 10(3) copies, while no T. pallidum DNA could be detected in the M131 group. At approximately the mean time to lesion appearance in the IRS and M131 groups (17 and 20 days, respectively), the numbers of T. pallidum DNA copies were still 5- and 30-fold less, respectively, than those in the control group at these times. By 30 days postchallenge, the T. pallidum DNA copy numbers were similar in all three groups. These findings indicate that the delays in appearance of syphilitic lesions conferred by IRS and M131 corresponded to a marked decrease in treponemal numbers during the course of lesion development.
authors.affiliation: A2-087G, Center for Health Sciences, UCLA School of Medicine, Los Angeles, CA 90095, USA.
authors.forename: Cheryl I
authors.initials: CI
authors.lastname: Champion
authors.forename: David R
authors.initials: DR
authors.lastname: Blanco
authors.forename: Michael A
authors.initials: MA
authors.lastname: Lovett
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D019742:Chemokines, CC; D004195:Disease Models, Animal; D018628:Gene Dosage; D007116:Immunization, Passive; D016133:Polymerase Chain Reaction; D011817:Rabbits; D013587:Syphilis / Q000276:immunology* / Q000517:prevention & control*; D014210:Treponema pallidum / Q000235:genetics / Q000276:immunology; D014764:Viral Proteins
chemical_list: D000911:Antibodies, Monoclonal; D019742:Chemokines, CC; D014764:Viral Proteins; C120682:m131 protein, Mouse cytomegalovirus 1